WO2006005268A3 - Pharmaceutical composition containing polypeptide fragments of serralysins - Google Patents

Pharmaceutical composition containing polypeptide fragments of serralysins Download PDF

Info

Publication number
WO2006005268A3
WO2006005268A3 PCT/CU2005/000003 CU2005000003W WO2006005268A3 WO 2006005268 A3 WO2006005268 A3 WO 2006005268A3 CU 2005000003 W CU2005000003 W CU 2005000003W WO 2006005268 A3 WO2006005268 A3 WO 2006005268A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
serralysins
polypeptide fragments
pharmaceutical composition
composition containing
Prior art date
Application number
PCT/CU2005/000003
Other languages
Spanish (es)
French (fr)
Other versions
WO2006005268A2 (en
Inventor
Perez Maria Del Car Abrahantes
Gonzalez Jesus Reyes
Rios Gloria Veliz
Diaz Eduardo Martinez
Gonzalez Caridad Anais Gasmuri
Suarez Jose Garcia
Romero Monica Bequet
Lopez Luis Javier Gonzalez
Serra Lila Rosa Castellanos
Sosa Manuel Selman-Housein
Riera Raul Gomez
Cowley Jorge Victor Gavilondo
Original Assignee
Ct Ingenieria Genetica Biotech
Perez Maria Del Car Abrahantes
Gonzalez Jesus Reyes
Rios Gloria Veliz
Diaz Eduardo Martinez
Gonzalez Caridad Anais Gasmuri
Suarez Jose Garcia
Romero Monica Bequet
Lopez Luis Javier Gonzalez
Serra Lila Rosa Castellanos
Sosa Manuel Selman-Housein
Riera Raul Gomez
Cowley Jorge Victor Gavilondo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200531578T priority Critical patent/SI1787653T1/en
Priority to MX2007000339A priority patent/MX2007000339A/en
Application filed by Ct Ingenieria Genetica Biotech, Perez Maria Del Car Abrahantes, Gonzalez Jesus Reyes, Rios Gloria Veliz, Diaz Eduardo Martinez, Gonzalez Caridad Anais Gasmuri, Suarez Jose Garcia, Romero Monica Bequet, Lopez Luis Javier Gonzalez, Serra Lila Rosa Castellanos, Sosa Manuel Selman-Housein, Riera Raul Gomez, Cowley Jorge Victor Gavilondo filed Critical Ct Ingenieria Genetica Biotech
Priority to EP05762122A priority patent/EP1787653B1/en
Priority to US11/631,880 priority patent/US8076297B2/en
Priority to KR1020077002589A priority patent/KR101365056B1/en
Priority to PL05762122T priority patent/PL1787653T3/en
Priority to JP2007519599A priority patent/JP4914350B2/en
Priority to DK05762122.9T priority patent/DK1787653T3/en
Priority to BRPI0513136-7A priority patent/BRPI0513136A/en
Priority to RS20120391A priority patent/RS52448B/en
Priority to AU2005262159A priority patent/AU2005262159B2/en
Priority to CA2572984A priority patent/CA2572984C/en
Priority to ES05762122T priority patent/ES2389126T3/en
Publication of WO2006005268A2 publication Critical patent/WO2006005268A2/en
Publication of WO2006005268A3 publication Critical patent/WO2006005268A3/en
Priority to HRP20120682TT priority patent/HRP20120682T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/265—Enterobacter (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of the sequence to the end of the molecule, which can be combined with one another and, optionally, with prodigiosins which potentiate the anti-tumour effect of the composition. The prodigiosins in the composition can be at a concentration of between 0.1 - 100 nM. The anti-proliferative action of the composition is provided by apoptotic mechanisms. The in vivo administration of the inventive composition has an anti-tumour effect, an anti-angiogenic effect and protects against malignant tumours.
PCT/CU2005/000003 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins WO2006005268A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
BRPI0513136-7A BRPI0513136A (en) 2004-07-08 2005-07-05 pharmaceutical composition containing serralisin polypeptide fragments
DK05762122.9T DK1787653T3 (en) 2004-07-08 2005-07-05 Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins
EP05762122A EP1787653B1 (en) 2004-07-08 2005-07-05 Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins
MX2007000339A MX2007000339A (en) 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins.
KR1020077002589A KR101365056B1 (en) 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins
PL05762122T PL1787653T3 (en) 2004-07-08 2005-07-05 Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins
RS20120391A RS52448B (en) 2004-07-08 2005-07-05 Antitumoral pharmaceutical composition containing polypeptide fragments of serralyysins
SI200531578T SI1787653T1 (en) 2004-07-08 2005-07-05 Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins
US11/631,880 US8076297B2 (en) 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins
JP2007519599A JP4914350B2 (en) 2004-07-08 2005-07-05 Pharmaceutical composition comprising a polypeptide fragment of seralisins
AU2005262159A AU2005262159B2 (en) 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins
CA2572984A CA2572984C (en) 2004-07-08 2005-07-05 A pharmaceutical composition containing polypeptide fragments of the serralysins
ES05762122T ES2389126T3 (en) 2004-07-08 2005-07-05 Antitumor pharmaceutical composition containing polypeptide serralisin fragments
HRP20120682TT HRP20120682T1 (en) 2004-07-08 2012-08-27 Pharmaceutical composition containing polypeptide fragments of serralysins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040147A CU23475A1 (en) 2004-07-08 2004-07-08 PHARMACEUTICAL COMPOSITION CONTAINING SERRALISINE POLYPEPTIDE FRAGMENTS
CU2004-0147 2004-07-08

Publications (2)

Publication Number Publication Date
WO2006005268A2 WO2006005268A2 (en) 2006-01-19
WO2006005268A3 true WO2006005268A3 (en) 2006-03-09

Family

ID=40259088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2005/000003 WO2006005268A2 (en) 2004-07-08 2005-07-05 Pharmaceutical composition containing polypeptide fragments of serralysins

Country Status (22)

Country Link
US (1) US8076297B2 (en)
EP (1) EP1787653B1 (en)
JP (1) JP4914350B2 (en)
KR (1) KR101365056B1 (en)
AR (1) AR050255A1 (en)
AU (1) AU2005262159B2 (en)
BR (1) BRPI0513136A (en)
CA (1) CA2572984C (en)
CU (1) CU23475A1 (en)
CY (1) CY1114201T1 (en)
DK (1) DK1787653T3 (en)
ES (1) ES2389126T3 (en)
HR (1) HRP20120682T1 (en)
MX (1) MX2007000339A (en)
MY (1) MY150858A (en)
PL (1) PL1787653T3 (en)
PT (1) PT1787653E (en)
RS (1) RS52448B (en)
RU (1) RU2396274C2 (en)
SI (1) SI1787653T1 (en)
WO (1) WO2006005268A2 (en)
ZA (1) ZA200700178B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461302B2 (en) * 2004-11-23 2013-06-11 Zymogenetics, Inc. Purification of recombinant human factor XIII
CN101675355B (en) 2007-05-04 2017-04-19 皇家飞利浦电子股份有限公司 Hybrid mr/pet with correction for radiation absorption by mr coil
CU23950B1 (en) * 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología CYCLIC PEPTIDES WITH ANTINEOPLASSIC AND ANTIANGIOGENIC ACTIVITY
TWI746449B (en) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 Methods for treating cancer using apilimod
CN109295041A (en) * 2018-10-10 2019-02-01 宁波希诺亚海洋生物科技有限公司 With active polypeptide of serrapeptase and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519021A1 (en) * 1981-12-28 1983-07-01 Takeda Chemical Industries Ltd Stabilised lyophilised powders - contg. serrapeptase and lactose, sucrose, gelatin, or aspartic or glutamic acid
EP0226800A2 (en) * 1985-11-15 1987-07-01 Takeda Chemical Industries, Ltd. Novel recombinant gene and use thereof
WO1999015690A1 (en) * 1997-09-20 1999-04-01 Korea Institute Of Science And Technology Novel serratia marcescens strain, prodigiosin and the use of the same as an immunosuppressive
US20040185566A1 (en) * 2003-03-19 2004-09-23 Peter Salamone Polypeptides toxic to nematodes and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519021A1 (en) * 1981-12-28 1983-07-01 Takeda Chemical Industries Ltd Stabilised lyophilised powders - contg. serrapeptase and lactose, sucrose, gelatin, or aspartic or glutamic acid
EP0226800A2 (en) * 1985-11-15 1987-07-01 Takeda Chemical Industries, Ltd. Novel recombinant gene and use thereof
WO1999015690A1 (en) * 1997-09-20 1999-04-01 Korea Institute Of Science And Technology Novel serratia marcescens strain, prodigiosin and the use of the same as an immunosuppressive
US20040185566A1 (en) * 2003-03-19 2004-09-23 Peter Salamone Polypeptides toxic to nematodes and methods of use

Also Published As

Publication number Publication date
EP1787653A2 (en) 2007-05-23
SI1787653T1 (en) 2012-10-30
AR050255A1 (en) 2006-10-11
AU2005262159B2 (en) 2011-08-18
CU23475A1 (en) 2009-12-17
WO2006005268A2 (en) 2006-01-19
PL1787653T3 (en) 2012-11-30
JP2008505129A (en) 2008-02-21
MY150858A (en) 2014-03-14
BRPI0513136A (en) 2008-04-29
US8076297B2 (en) 2011-12-13
CA2572984A1 (en) 2006-01-19
RU2007104776A (en) 2008-08-20
US20110218138A1 (en) 2011-09-08
HRP20120682T1 (en) 2012-09-30
CA2572984C (en) 2014-12-09
ES2389126T3 (en) 2012-10-23
RU2396274C2 (en) 2010-08-10
CY1114201T1 (en) 2016-08-31
ZA200700178B (en) 2008-06-25
PT1787653E (en) 2012-09-06
KR20070042542A (en) 2007-04-23
JP4914350B2 (en) 2012-04-11
EP1787653B1 (en) 2012-06-06
MX2007000339A (en) 2007-03-12
AU2005262159A1 (en) 2006-01-19
DK1787653T3 (en) 2012-09-17
KR101365056B1 (en) 2014-02-21
RS52448B (en) 2013-02-28

Similar Documents

Publication Publication Date Title
IL184554A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
WO2009051706A3 (en) Peptide compounds for treating obesity and insulin resistance
WO2006136607A3 (en) Use of hydrophobin-polypeptides and conjugates from hydrophobin-polypeptides having active and effect agents and the production thereof and use thereof in the cosmetic industry
CL2006003672A1 (en) COMPOUNDS DERIVED FROM PIRIMIDO- [4,5-B] -OXAZINAS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF MELLITUS DIABETES AND / OR OBESITY.
UA94244C2 (en) Antagonist antibody directed against calcitonin gene-related peptide and pharmaceutical composition comprising the same
WO2006116716A3 (en) Materials and methods for enhanced degradation of mutant proteins associated with human disease
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2006083971A3 (en) Dr5 antibodies and uses thereof
HK1071066A1 (en) Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
EA200701793A1 (en) COMPOSITIONS OF A NOZETAXEL AND ITS ANALOGUES COMPOSING OF NANOPARTICLES
WO2006005268A3 (en) Pharmaceutical composition containing polypeptide fragments of serralysins
WO2007095288A3 (en) Methionine-containing protein or peptide compositions and methods of making and using
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
SG149059A1 (en) Gastrointestinal proliferative factor and uses thereof
WO2008045976A3 (en) Compositions and methods for treating and diagnosing cancers
WO2007044809A3 (en) Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
AR058308A1 (en) VIP FRAGMENTS AND METHODS OF USE OF THE SAME
EP1978034A4 (en) Anti-periostin antibody and pharmaceutical composition for preventing or treating periostin-related disease containing the same
WO2006023356A3 (en) Selective vpac2 receptor peptide agonists
WO2007101146A3 (en) Selective vpac2 receptor peptide agonists
WO2007133828A3 (en) Selective vpac2 receptor peptide agonists
WO2008028934A8 (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
HK1123507A1 (en) Composition for preventing or treating damages of the mucosa in the gastrointestinal tracts
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
WO2006103354A3 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007/00178

Country of ref document: ZA

Ref document number: 200700178

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2007519599

Country of ref document: JP

Ref document number: 2572984

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000339

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 578/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005762122

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077002589

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 07011575

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2005262159

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007104776

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005262159

Country of ref document: AU

Date of ref document: 20050705

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005262159

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005762122

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11631880

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0513136

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2012/0391

Country of ref document: RS

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)